SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

XRP is a decentralized digital asset and the native token of the XRP Ledger, a Layer 1 blockchain designed for high-performance global payments. Its primary value proposition is offering a fast, cost-effective alternative to traditional banking systems by enabling near-instant cross-border settlements that finalize in three to five seconds. By serving as a neutral bridge asset between different fiat currencies, it helps financial institutions lower liquidity costs and eliminates the need for pre-funded accounts.  The network is unique because it utilizes a federated consensus protocol instead of energy-intensive mining or staking. This system achieves deterministic finality through a Unique Node List of trusted validators who must reach an eighty percent agreement threshold to permanently record transactions. This infrastructure supports a sustained throughput of 1,500 transactions per second and includes a built-in decentralized exchange that allows for the automated trading of any tokenized asset without intermediaries.  The project traces its origins back to 2004 with Ryan Fugger before being co-founded in its modern form by Jed McCaleb and Chris Larsen. The company, now known as Ripple, works with major financial institutions as partners and investors to build global payment solutions. To protect the network from spam, a small amount of XRP is burned during every transaction, and the token is further utilized by institutions as collateral to access traditional markets and manage digital asset infrastructure.  Institutional adoption of the asset reached a major milestone in November 2025 when the SEC approved the first wave of spot XRP ETFs. These products, offered by major issuers including Bitwise, Grayscale, 21Shares, Canary Capital, and Franklin Templeton, are now listed on prominent exchanges like the NYSE Arca, Nasdaq, and Cboe BZX. While Ripple remains a key contributor to the ecosystem, the underlying XRP Ledger continues to operate as an open-source and decentralized network.

Ripple

The community is currently locked in a heated debate as the asset struggles to maintain the psychological support level of one dollar, with many investors citing regulatory uncertainty and delays around the Clarity Act as primary drivers for the recent downward pressure. While bearish voices predict further capitulation, a vocal contingent of long-term holders remains bullish, viewing the current price action as an accumulation opportunity and maintaining conviction in the project's long-term utility.

Riot Platforms, Inc. is a bitcoin mining company, which engages in the provision of special cryptocurrency mining computers. It invests in Verady, Coinsquare, and Tess. It operates through the Bitcoin Mining and Engineering segments. The Bitcoin Mining segment focuses on maximizing ability to successfully mine Bitcoin by growing hash rate. The Engineering segment designs and manufactures power distribution equipment and custom engineered electrical products that provides them the ability to vertically integrate many of the critical electrical components and engineering service. The company was founded on July 24, 2000 and is headquartered in Castle Rock, CO.

Riot Platforms Inc

Riot Platforms is surging as investors closely monitor the company's strategic pivot toward AI data center infrastructure and potential large-scale leasing deals. Community discourse is heavily focused on the company's power capacity at its Texas facilities, with speculation regarding upcoming tenant agreements driving significant volatility and intense debate over potential share dilution.

RUM Group, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

RUM Group Inc. - Ordinary Shares - Class A

RUM Group Inc.

Rumble is trending as investors focus on the company's strategic pivot toward AI infrastructure following its acquisition of Northern Data, a move that has significantly expanded its GPU capacity and data center footprint. The community is actively debating the potential for a massive short squeeze due to record-high short interest, while simultaneously analyzing the upcoming earnings report and formal guidance as key catalysts for a long-term re-rating.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is currently trending as investors scrutinize the company's recent trial readouts and anticipation builds for an upcoming BLA submission in late September. Community sentiment is deeply polarized, with bulls pointing to the company's strong cash position and best-in-class pipeline potential, while bears highlight concerns over clinical data efficacy and potential dilution from recent equity incentive plan filings.

Babcock & Wilcox Enterprises, Inc. engages in the provision of fossil and renewable power generation and environmental equipment. It operates through the B&W segment. The company was founded by George H. Babcock, Stephen Wilcox, Jr., and Joseph P. Manton in 1856 and is headquartered in Akron, OH.

Babcock & Wilcox Enterprises Inc

Babcock & Wilcox is trending as investors react to a $200 million stock offering priced at $18.50, with many viewing the institutional participation and use of proceeds for AI-related energy infrastructure as a bullish signal for long-term growth. Community discussion remains focused on the company's massive order backlog and potential for a short squeeze, despite ongoing volatility and debate over the immediate impact of the dilution.

Chipotle Mexican Grill, Inc. engages in the business of developing and operating restaurants that serve a relevant menu of burritos, burrito bowls, quesadillas, tacos, and salads made using fresh, high-quality ingredients. The company was founded by Steve Ells in 1993 and is headquartered in Newport Beach, CA.

Chipotle Mexican Grill

Chipotle stock is experiencing significant volatility driven by a combination of a post-earnings guidance hike, recent salmonella-related supply chain concerns, and active debate among retail traders regarding potential accumulation versus further downside. While some investors view the recent dip as a buying opportunity, others remain skeptical, citing long-term technical resistance and ongoing concerns over food safety and portion sizes.

Definium Therapeutics, Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn on July 26, 2010 and is headquartered in New York, NY.

Definium Therapeutics Inc.

Definium Therapeutics is trending following the announcement of positive Phase 3 trial results for its depression treatment, triggering a significant stock surge as investors weigh the clinical success against potential upcoming share dilution. The community is actively debating the stock's valuation, questioning whether to capitalize on the rally or hold for anticipated Phase 3 data readouts for other indications later this year.

On Holding AG engages in the development and distribution of sports products such as footwear, apparel, and accessories for high-performance running, outdoor, all-day activities, and tennis. It sells its products worldwide through independent retailers and global distributors, its own online presence, and its own stores. The company was founded by David Allemann, Olivier Bernhard, and Caspar Coppetti in January 2010 and is headquartered in Zurich, Switzerland.

On Holding AG - Ordinary Shares Class A

On Holding AG

On Holding is experiencing significant market interest driven by its strong revenue growth, successful direct-to-consumer expansion, and aggressive international scaling in the APAC region. While some community members debate the impact of potential tariff headwinds and leadership changes, active discussions highlight the brand's premium market positioning as a primary catalyst for long-term optimism.

Sea Ltd. is an internet and mobile platform company, which engages in the provision of online gaming services. It operates through the following segments: Digital Entertainment, E-Commerce, and Digital Financial Services. The Digital Entertainment segment offers and develops mobile and PC online games. The E-Commerce segment manages a third-party marketplace through the Shopee mobile app and websites that connect buyers and sellers. The Digital Financial Services segment includes a variety of payment services and loans to individuals and businesses through SeaMoney. Sea was founded by Xiao Dong Li, Gang Ye, and Jing Ye Chen on May 8, 2009 and is headquartered in Singapore.

Sea Ltd - ADR

Sea Ltd is currently trending as investors debate its valuation following a significant earnings beat and revenue growth, leading to active community discussions about its long-term potential as a diversified digital ecosystem. Traders are closely monitoring technical support levels and recent institutional activity, weighing the company's strong operational momentum against broader market volatility and insider selling patterns.

Archer Aviation, Inc. engages in the development of electric vertical take-off and landing (eVTOL) aircraft. The company was founded by Brett Adcock and Adam Goldstein on October 16, 2018, and is headquartered in San Jose, CA.

Archer Aviation Inc - Ordinary Shares - Class A

Archer Aviation Inc

Archer Aviation is trending following the announcement of a definitive agreement to acquire three Boeing subsidiariesWisk Aero, Insitu, and SkyGridcoupled with a significant strategic investment from Boeing. Investors are actively debating the long-term potential of this expanded aerospace platform and the impact of the resulting dilution, while awaiting the upcoming earnings report to assess the company's path to commercialization.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

TBPH Meets Q2 Earnings Estimates, to be Acquired by Zymeworks

Theravance's Q2 earnings match estimates. Cost cuts and a $929 million Zymeworks deal follow ampreloxetine's discontinuation.

Zymeworks Inc. (ZYME) Reports Q2 Loss, Beats Revenue Estimates

Zymeworks (ZYME) delivered earnings and revenue surprises of -10.71% and +25.41%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

A Clinical-Stage Cancer Company Is Putting AI to Work at the Bench, Designing Its Next Generation of Tumor-Targeting Drugs

A Clinical-Stage Cancer Company Is Putting AI to Work at the Bench, Designing Its Next Generation of Tumor-Targeting Drugs A Clinical-Stage Cancer Company Is Putting AI to Work at the Bench, Designing Its Next Generation of Tumor-Targeting Drugs PR Newswire SAN FRANCISCO, July 6, 2026 Issued on...

Is Zymeworks Inc. (ZYME) Stock an Undervalued Biotech Opportunity With Oncology Growth Ahead?

Is Zymeworks Inc. (ZYME) Stock an Undervalued Biotech Opportunity With Oncology Growth Ahead...

Theravance Stock Down 3% After Zymeworks Announces Buyout

TBPH falls after agreeing to a $929 million all-cash acquisition by Zymeworks, following a strategic review triggered by its failed ampreloxetine program.

Zymeworks Targets Long-Term Cash Generation Through Theravance Acquisition

Zymeworks will acquire Theravance Biopharma for $929 million, adding YUPELRI cash flows and expanding its portfolio.read more...

Zymeworks To Buy Theravance Biopharma In $929M Deal – A Look At What This Deal Means For TBPH Shareholders

Equity

Theravance Biopharma shareholders will receive a contingent value right (CVR) under which they will get 80% of the net proceeds from any future license, divestiture, or monetization of ampreloxetine over the next ten years.


Gandeeva and Zymeworks Use Cryo-EM to Accelerate Antibody Drug Discovery

Gandeeva and Zymeworks Use Cryo-EM to Accelerate Antibody Drug Discovery Gandeeva and Zymeworks Use Cryo-EM to Accelerate Antibody Drug Discovery PR Newswire VANCOUVER, BC, June 18, 2026 Vancouver-based biotech companies Gandeeva Therapeutics and Zymeworks have partnered to generate cryo-EMbased...

Zymeworks (ZYME) Q1 2026 Earnings Transcript

@media (max-width: 768px) {
 .image-container {
 width: 100% !important;
 float: none !important;
 margin: 0 0 1rem 0 !important;
 }
 }

Image source: The Mo...

Zymeworks Inc. (ZYME) Reports Q1 Loss, Misses Revenue Estimates

Zymeworks (ZYME) delivered earnings and revenue surprises of -510.13% and -94.63%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Zymeworks, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Its product includes Zanidatamab, which is a novel bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Zanidatamab's unique binding properties result in multiple mechanisms of action that may enable it to address unmet need in patient populations with HER2-expressing cancers. The company was founded on September 8, 2003 and is headquartered in Middletown, DE.

Zymeworks BC Inc

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '26	$2.17	--	--	N/A
Q2 '26	-$0.57	-$0.62	-9.23%	MISSED
Q1 '26	-$0.30	-$0.59	-98.76%	MISSED
Q4 '25	-$0.46	-$0.55	-19.27%	MISSED
Q3 '25	-$0.29	-$0.26	11.77%	BEAT

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q2 '26

Historical Earnings